Emergency Regulation Change Regarding Prophylactic Treatment of Newborns’ Eyes

Background
Ophthalmia neonatorum is defined as conjunctivitis occurring within the first 4 weeks of life. While there are many causes of ophthalmia neonatorum, Neisseria gonorrhoeae is most commonly associated with more severe disease. As is true in most states, Alaska law requires that a prophylactic agent be instilled into the eyes of all newborn infants to prevent gonococcal ophthalmia neonatorum. Erythromycin (0.5%) ophthalmic ointment is the recommended prophylactic treatment of choice.

On August 31, 2009, the Centers for Disease Control and Prevention (CDC) indicated that there is a national shortage of erythromycin (0.5%) ophthalmic ointment. According to CDC, the shortage is due to a change in manufacturers. Fera Pharmaceuticals, which recently acquired the rights to erythromycin (0.5%) ophthalmic ointment, and Bausch & Lomb, which also manufactures the product, are working with the Food and Drug Administration (FDA) to increase production and supply. Guidelines for securing existing supplies and alternative treatment guidelines for providers unable to obtain an adequate supply are available online.1,2

Emergency Regulation Change
Alaska regulation 7 AAC 27.111 regarding the prophylactic treatment of newborns’ eyes was adopted in 1980,3 and allowed for the use of three medications: 1% silver nitrate ophthalmic solution, tetracycline ophthalmic ointment, and erythromycin (0.5%) ophthalmic ointment. The first two medications are no longer available commercially in pediatric dosages in the United States.

On September 18, 2009, the Alaska Department of Health and Social Services (DHSS) adopted, as an emergency regulation, changes to 7 AAC 27.111 (Box).3 These changes were needed in order to allow DHSS to adopt the recommended alternative medications listed by the CDC for the prophylactic treatment of newborns’ eyes and to eliminate recommendations for the use of alternative regimens that are no longer available in pediatric dosages in the United States.

Discussion
The updated CDC recommendations for prevention of ophthalmia neonatorum include medications that are not FDA-approved. These medications are recommended on the basis of available data on pharmacology and gonococcal microbiologic sensitivity, but no data exist regarding the efficacy of these products for the prophylactic treatment of ophthalmia neonatorum.2

In addition to routine newborn prophylaxis, the 2006 STD Treatment Guidelines outline recommended prophylactic treatment for infants whose mothers have gonococcal infection and for management of infants born to mothers who have untreated chlamydia.3 Empiric treatment is recommended for infants exposed to gonorrhea, while monitoring for development of symptoms prior to initiating treatment is recommended for infants exposed to chlamydia.3,5

DHSS intends to make the emergency changes to 7 AAC 27.111 permanent on January 15, 2010, following a public comment period ending October 23, 2009 at 5:00 PM. Instructions for submission of public comment can be found at the DHSS website.3

Recommendations
1. Providers should review their supplies of erythromycin ophthalmic ointment (0.5%) routinely and reserve current supplies for neonatal prophylaxis use. For normal replacement supplies, contact the wholesale distributor directly. For severely low supplies (i.e., depletion within a week), contact the wholesale distributor or call Bausch & Lomb customer service at 1-800-523-3000 directly.
2. When erythromycin (0.5%) ophthalmic ointment is not available, Azasite® (Azithromycin Ophthalmic Solution 1%, Inspire Pharmaceuticals) is an acceptable alternative.
3. If neither Azasite® nor Erythromycin Ophthalmic Ointment (0.5%) is available, the following are acceptable alternatives: Gentak® (Gentamicin Ophthalmic Ointment 0.3%, Akorn) or Tobrex® (Tobramycin Ophthalmic Ointment 0.3%, Alcon Laboratories).
4. If none of the above preparations are available, a fluoroquinolone ophthalmic ointment: Ciloxan® (Ciprofloxacin Ophthalmic Ointment 0.3%, Alcon Laboratories) can be used, but this is a less suitable alternative given data on possible gonococcal antimicrobial resistance.
5. Betadine (povidone iodine) is not recommended due to the potential confusion with and possible use of the more familiar detergent formulation, which can be harmful.
6. Providers should be alert to the possibility of failure of prophylaxis.2

References
2. Centers for Disease Control and Prevention Guidance on Shortage of Erythromycin (0.5%) Ophthalmic Ointment – September 2009. Available at: http://www.cdc.gov/std/treatment/2006/erythromycinOintmentShortage.htm
3. 7 AAC 27.111. Prophylactic treatment of newborn’s eyes. Available at: http://search.courts.state.ak.us/casefinder/casefile.jsp?caseid=027/section111.htm
5. Centers for Disease Control and Prevention, 2006 STD Treatment Guidelines. Available at: www.cdc.gov/std/treatment

State of Alaska Bulletin
Epidemiology

Department of Health and Social Services
William H. Hogan, MSW, Commissioner
3600 C Street, Suite 540
Anchorage, Alaska 99503
http://www.epi.alaska.gov

Division of Public Health
Ward Hurburton, MD, MPH, CMO/Director
Local (907) 269-8000
24 Hour Emergency (900) 478-0084

Editor: Joe McLaughlin, MD, MPH
Bulletin No. 25
September 24, 2009

(Contributed by Susan Jones, RN, MN and Daniel Keebler, SM, Section of Epidemiology; and Stephanie Birch, RNC, MPH, MS, FNP, Section of Women’s, Children and Family Health.)